Bedaquiline: What might the future hold?

Webinar held on Friday 30th June 2023 After decades without new drugs for TB, bedaquiline (BDQ) has changed the TB treatment landscape as the first of a series of new drugs to be licensed for drug-resistant TB. However there is already drug resistance. In this workshop, co-organised by UCL-TB and the Africa Health Research Institute (AHRI), people with different expertises discuss the current situation and how we might manage roll out of this important new antibiotic. Full programme and biographical details of panellists: https://www.ucl.ac.uk/tb/bedaquiline-... 00:00 Welcome and introduction Limakatso Lebina (AHRI) and Marc Lipman (UCL) What do we know? Short presentations on the state of current knowledge: 06:00 Patient perspective (Oxana Rucsineanu, TB survivor, Society of Moldova against Tuberculosis) 18:44 Patient perspective (Phumeza Tisile, TB survivor, Advocacy Officer, TB Proof, South Africa) 28:10 Clinical Practice (Lancelot Pinto, P.D.Hinduja National Hospital and Medical Research Centre, Mumbai, India) 37:00 BDQ Resistance (Grant Theron, Stellenbosch University, South Africa) 45:43 Trials/Future Directions (Francesca Conradie, University of the Witwatersrand, South Africa) 53:43 Policy (Teck Chuan Voo, National University, Singapore) Initial comments from other panellists 1:01:25 Trials/Future Directions (Derek Sloan, University of St Andrews, UK) 1:03:29 BDQ Resistance (Rob Warren, Stellenbosch University, South Africa) 1:06:08 Clinical Practice (Chen-Yuan Chiang, Taipei Medical University, Taiwan) 1:08:35 Policy (Christoph Lange, University of Lübeck, Germany) 1:10:50 General Discussion